Frontline Treatment Landscape in Transplant-Eligible Patients with NDMM

Opinion
Video

Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD, discuss the overall frontline treatment landscape for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM).

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following question:

      • What is the frontline treatment landscape for transplant-eligible patients with multiple myeloma?
      Recent Videos
      KEYMAKER-U03: Lenvatinib Plus Belzutifan Emerges as a Promising Option in Advanced RCC and New Directions From ASCO GU 2025
      KEYMAKER-U03: Lenvatinib Plus Belzutifan Emerges as a Promising Option in Advanced RCC and New Directions From ASCO GU 2025
      IO-IO vs IO-TKI: Expert Approaches to First-Line RCC Treatment Selection
      IO-IO vs IO-TKI: Expert Approaches to First-Line RCC Treatment Selection
      Clinical Pearls: Synthesizing Risk Assessment and Response Patterns in Advanced RCC Management
      Clinical Pearls: Synthesizing Risk Assessment and Response Patterns in Advanced RCC Management
      Risk Score Stability and Post Lenvatinib Plus Pembrolizumab Treatment Selection in RCC
      Risk Score Stability and Post Lenvatinib Plus Pembrolizumab Treatment Selection in RCC
      From IMDC Risk Assessments to Sequencing Strategies: Clinical Implications From CLEAR Post Hoc Analyses
      From IMDC Risk Assessments to Sequencing Strategies: Clinical Implications From CLEAR Post Hoc Analyses
      From Initial Response to Long-Term Outcomes: Optimizing RCC Treatment Strategies Across the Care Continuum
      From Initial Response to Long-Term Outcomes: Optimizing RCC Treatment Strategies Across the Care Continuum
      Tumor Burden Impact on Postprogression Survival: Optimizing Strategies for Maximum Response in RCC
      Tumor Burden Impact on Postprogression Survival: Optimizing Strategies for Maximum Response in RCC
      CLEAR Trial Insights on Lenvatinib Plus Pembrolizumab: Depth of Response and Clinical Outcomes in Advanced RCC
      CLEAR Trial Insights on Lenvatinib Plus Pembrolizumab: Depth of Response and Clinical Outcomes in Advanced RCC
      3 experts in this video
      Key Takeaways and Future in Advanced Gastric Cancer Treatment
      4 experts are featured in this series.
      Real World Experience of CAR-T in MM Patients
      Related Content
      Cytokine release syndrome events primarily occurred during step-up and the first full dosing cycle in patients with relapsed/refractory multiple myeloma.

      Talquetamab Elicits Sustained Responses in Pre-Treated R/R Multiple Myeloma

      Roman Fabbricatore
      April 1st 2025
      Article

      Cytokine release syndrome events primarily occurred during step-up and the first full dosing cycle in patients with relapsed/refractory multiple myeloma.

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

      Samantha Shenoy, NP, MSN
      October 14th 2024
      Podcast

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Updated findings from the CENTAURUS study may support the use of daratumumab monotherapy in those with intermediate- or high-risk smoldering myeloma.

      Daratumumab Continues to Show Activity in Smoldering Multiple Myeloma

      Russ Conroy
      March 23rd 2025
      Article

      Updated findings from the CENTAURUS study may support the use of daratumumab monotherapy in those with intermediate- or high-risk smoldering myeloma.

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

      James R. Berenson, MD, FACP
      September 30th 2024
      Podcast

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Final OS analysis data from the OPTIMISMM trial support sequencing a pomalidomide-based regimen after lenalidomide failure in relapsed/refractory myeloma.

      Pomalidomide Combo Sustains Improved Outcomes in Pretreated R/R Myeloma

      Russ Conroy
      March 19th 2025
      Article

      Final OS analysis data from the OPTIMISMM trial support sequencing a pomalidomide-based regimen after lenalidomide failure in relapsed/refractory myeloma.

      Real-World KRd Results Comparable to Phase 3 Trial Results in Myeloma

      Real-World KRd Results Comparable to Phase 3 Trial Results in Myeloma

      Tim Cortese
      March 14th 2025
      Article

      Carfilzomib, lenalidomide, and dexamethasone results from the real world continued to show effective responses and a tolerable safety profile.